— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...
SEATTLE, January 27, 2026--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
The fact that the complement system is activated during immune-complex glomerular disease has been known for nearly 50 years. Detection of complement deposition in the glomerulus using immunochemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results